Compare UEIC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | KLRS |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3M | 46.0M |
| IPO Year | 1995 | N/A |
| Metric | UEIC | KLRS |
|---|---|---|
| Price | $3.76 | $10.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $9.25 | ★ $20.67 |
| AVG Volume (30 Days) | 48.6K | ★ 54.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $394,879,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.69 | $2.14 |
| 52 Week High | $7.90 | $11.90 |
| Indicator | UEIC | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 55.24 |
| Support Level | $3.68 | $8.08 |
| Resistance Level | $3.79 | $10.36 |
| Average True Range (ATR) | 0.17 | 1.11 |
| MACD | -0.05 | 0.10 |
| Stochastic Oscillator | 5.08 | 71.61 |
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.